title: The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis.
abstract: Canakinumab is indicated for patients with frequent gouty arthritis attacks who cannot be managed with standard-of-care medication, and should be used according to the labeled indication. Given its mechanism of action, physicians need to be aware of the potential contraindications and precautions with its use. When deciding as to whether a patient with gouty arthritis is an appropriate candidate for canakinumab treatment, several key clinical considerations should be kept in mind, which are discussed herein.
authors.affiliation: Head, Department of Rheumatology, Lariboisière Hospital, Assistance Publique Hôpitaux de Paris, University Paris VII, Paris, France. Electronic address: thomas.bardin@lrb.aphp.fr.
authors.forename: Thomas
authors.initials: T
authors.lastname: Bardin
authors.affiliation: Professor of Medicine, Department of Rheumatology, Enschede, Medisch Spectrum Twente, The Netherlands.
authors.forename: Martinus A F J
authors.initials: MA
authors.lastname: van de Laar
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015210:Arthritis, Gouty / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D000075202:Contraindications; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors*; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006074:Gout Suppressants; D053583:Interleukin-1beta; C541220:canakinumab
keywords: Canakinumab; Difficult-to-treat gouty arthritis; Interleukin (IL)-1β inhibitor; Monosodium urate crystals; Urate-lowering therapy